This company has been acquired
AVEO Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Key information
134.1%
Debt to equity ratio
US$38.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$77.40m |
| Equity | US$28.85m |
| Total liabilities | US$72.39m |
| Total assets | US$101.23m |
Recent financial health updates
Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04
Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23Recent updates
AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash
Oct 18Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money
Oct 04A Current Assessment On AVEO Pharmaceuticals
Aug 15Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt
Jun 21AVEO Pharmaceuticals Is Primed For A Breakout
May 24Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results
Mar 17AVEO Pharmaceuticals: Finally Ready To Reboot
Mar 09AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Mar 03AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Nov 23AVEO Pharmaceuticals: Sticking To The Plan
Oct 29AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
Jul 24AVEO Oncology: Time To Be Patient
Jun 07AVEO outlines 2021 outlook; initiates Phase 1 trial for cancer complication
Jan 07AVEO Oncology: Managing A Position Ahead Of Tivozanib's PDUFA
Dec 27Financial Position Analysis
Short Term Liabilities: AVEO's short term assets ($100.7M) exceed its short term liabilities ($42.4M).
Long Term Liabilities: AVEO's short term assets ($100.7M) exceed its long term liabilities ($30.0M).
Debt to Equity History and Analysis
Debt Level: AVEO has more cash than its total debt.
Reducing Debt: AVEO had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AVEO has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AVEO has sufficient cash runway for 2.9 years if free cash flow continues to reduce at historical rates of 12.7% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/01/21 16:27 |
| End of Day Share Price | 2023/01/19 00:00 |
| Earnings | 2022/09/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AVEO Pharmaceuticals, Inc. is covered by 18 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Madhu Kumar | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| James Birchenough | BMO Capital Markets U.S. (Historical) |